Oppenheimer & Co’s Capricor Therapeutics CAPR Stock Holding History

Oppenheimer & Co’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.82M	Buy	75,714 +12,048	+19%	+$365K	0.02%	674
2026 Q1	$1.94M	Sell	63,666 -17,147	-21%	-$457K	0.02%	604
2025 Q4	$2.33M	Sell	80,813 -54,600	-40%	-$713K	0.03%	503
2025 Q3	$976K	Sell	135,413 -27,123	-17%	-$200K	0.01%	902
2025 Q2	$1.61M	Buy	162,536 +33,341	+26%	+$352K	0.02%	648
2025 Q1	$1.23M	Buy	129,195 +24,964	+24%	+$347K	0.02%	714
2024 Q4	$1.44M	Buy	104,231 +35,823	+52%	+$628K	0.02%	657
2024 Q3	$1.04M	Buy	68,408 +13,762	+25%	+$68.1K	0.02%	775
2024 Q2	$261K	Buy	+54,646	New	+$305K	﹤0.01%	1247

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Oppenheimer & Co's CAPR Position: Q2 2026 in Review

Oppenheimer & Co increased its Capricor Therapeutics (CAPR) stake by 19% in Q2 2026, buying an estimated $365K and bringing the position to 75,714 shares worth $1.82M. The position accounts for 0.02% of the portfolio, ranked #674.

Oppenheimer & Co first reported a position in CAPR in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.33M in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Oppenheimer & Co held 75,714 shares of Capricor Therapeutics worth $1.82M as of Q2 2026.
Oppenheimer & Co bought 12,048 Capricor Therapeutics shares in Q2 2026, an estimated $365K.
Capricor Therapeutics made up 0.02% of Oppenheimer & Co's portfolio in Q2 2026, its #674 holding.
Oppenheimer & Co first reported a position in Capricor Therapeutics in Q2 2024 and has held it in 9 quarters since.
Oppenheimer & Co's Capricor Therapeutics position peaked at $2.33M in Q4 2025.
170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.